B of A Securities Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $25
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
B of A Securities analyst Travis Steed maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $35 to $25.
B of A Securities analyst Travis Steed maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $35 to $25.